Actively Recruiting
Percutaneous Thermal Ablation in Lung Tumors
Led by Assiut University · Updated on 2025-03-24
50
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Lung cancer has a high incidence globally, with Egypt having it as the third most common and most lethal cancer, affecting 16.9% of males and 3.8% of females. While surgery is the preferred treatment for stage 1 non-small cell lung cancer due to positive outcomes, it carries significant risks due to patient comorbidities. Non-invasive treatments like radio frequency ablation (RFA) and microwave ablation (MWA) are alternatives for those unable to undergo surgery. These techniques use energy to destroy tumor tissue with minimal invasiveness and can be guided by computed tomography to ensure accurate ablation.
CONDITIONS
Official Title
Percutaneous Thermal Ablation in Lung Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Lung cancer tumor smaller than 5 cm
- Metastasis to the lung
- Patients with lung cancer and multiple comorbidities who are unfit for surgery
You will not qualify if you...
- Lung cancer tumor larger than 5 cm
- Lung cancer stage II or higher
- Patients who cannot tolerate CT-guided needle placement for thermal ablation of lung tumors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Faculty of medicine
Asyut, Egypt, 71511
Actively Recruiting
Research Team
A
Abdulrahman F Ali, Bachelor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here